Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84478 trials found · Page 22 of 4224
-
Three-Drug attack on deadly lymphoma shows promise
Disease control Not yet recruitingExtranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens. Preclinical and clinical evidence suggests that PD-L1 is …
Phase: PHASE2 • Sponsor: LIANG WANG • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New hope for toughest leukemia: adding 'Super' white blood cells to transplant
Disease control Not yet recruitingAllogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death. Patients with certain mutations and those transplanted without first clearing their dis…
Phase: PHASE1, PHASE2 • Sponsor: University of Manchester • Aim: Disease control
Last updated Apr 06, 2026 14:14 UTC
-
New drug trial aims to protect kidneys in serious lupus complication
Disease control Recruiting nowThe goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to ans…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for melanoma patients who Don't respond to standard treatments
Disease control Recruiting nowThis clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immu…
Phase: PHASE2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Apr 14, 2026 13:08 UTC
-
Weekly shot aims to tame sleep apnea and shed pounds
Disease control Recruiting nowThe aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAP
Phase: PHASE3 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
One-Shot cell therapy aims to free myeloma patients from continuous treatment
Disease control Recruiting nowThis is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Phase: PHASE1 • Sponsor: Susan Bal • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
Experimental drug targets root cause of rare genetic obesity
Disease control Recruiting nowThis study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called monogenic obesity. Monogenic obesity is caused by a change in the leptin gene that keeps it from working properly. This causes the body to not be able to fe…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New stroke procedure aims to restore blood flow in Hard-to-Reach brain vessels
Disease control Recruiting nowThe investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of perfusion-guided endovascular treatment (EVT) compared to standard medical care for patients with acute ischemic stroke…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
New drug combo trial aims to stop Cancer's return after surgery
Disease control Recruiting nowThis study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with…
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
Weekly shot aims to help millions shed pounds in major obesity trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 w…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
New hope for Tough-to-Treat colorectal cancer patients
Disease control Not yet recruitingThe study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan subjects.
Phase: PHASE3 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
New hope for Tough-to-Treat cancer: experimental drug enters final testing
Disease control Recruiting nowBased on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New combo therapy aims to hold back advanced cancer with few spots
Disease control Recruiting nowThe combination of local consolidative therapy for oligometastases with systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease. However, a considerable proportion of patients still do no…
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Donor cells deployed to battle devastating brain infection
Disease control Recruiting nowThere is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in t…
Phase: PHASE2 • Sponsor: Hannover Medical School • Aim: Disease control
Last updated Apr 22, 2026 06:58 UTC
-
Could a daily pill slow type 1 diabetes progression?
Disease control Recruiting nowThe purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 22, 2026 06:58 UTC
-
New engineered immune cell therapy tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis Phase I/IIa clinical study is testing an experimental treatment called GYA01 (CART84) for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) whose disease has come back after treatment (relapsed) or did not respond to treatment (refractor…
Phase: PHASE1, PHASE2 • Sponsor: Gyala Therapeutics • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Personalized immune cell attack on advanced ovarian cancer
Disease control Recruiting nowThis Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Apr 06, 2026 14:19 UTC
-
New hope for Tough-to-Treat blood cancer: major trial tests promising drug
Disease control Recruiting nowThe purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 13, 2026 20:23 UTC
-
New CAR-T therapy aims to keep leukemia at bay for High-Risk adults
Disease control Recruiting nowThe researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual dise…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
Major trial tests promising new weapons against aggressive digestive cancers
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesop…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC